Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

Kim, Sunkyung; Campbell, Kimberly A.; Fox, Deborah J.; Matthews, Dennis J.; Valdez, Rodolfo

doi:10.1177/0883073814558120

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

Published Date:

Nov 20 2014

Publisher's site:

http://dx.doi.org/10.1177/0883073814558120 New Site Icon

Source:

J Child Neurol. 30(10):1275-1280.

[PDF - 498.45 KB]

Details:

Personal Authors:

Kim, Sunkyung ; Campbell, Kimberly A. ; Fox, Deborah J. ; Matthews, Dennis J. ; Valdez, Rodolfo ;

Corporate Authors:

MD STAR

Keywords:

[+]

Pubmed ID:

25414237

Pubmed Central ID:

PMC4439376

Description:

This population-based study examines the association between corticosteroid treatment and time to loss of ambulation, stratifying by treatment duration (short: 0.25-3 years, long: >3 years), among 477 Duchenne muscular dystrophy cases identified by the Muscular Dystrophy Surveillance Tracking and Research Network (MDSTARnet). Those cases who received short-term corticosteroid treatment had a time to loss of ambulation that was 0.8 years shorter (t test) and an annual risk of losing ambulation 77% higher than the untreated (Cox regression). Conversely, cases who received long-term corticosteroid treatment had a time to loss of ambulation that was 2 years longer and an annual risk of losing ambulation 82% lower than the untreated, up to age 11 years; after which the risks were not statistically different. The relationship of corticosteroids and time to loss of ambulation is more complex than depicted by previous studies limited to treatment responders or subjects who lost ambulation during study follow-up.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

CC999999/Intramural CDC HHS/United States
U01 DD000191/DD/NCBDD CDC HHS/United States
5 U01 DD000191/DD/NCBDD CDC HHS/United States

Supporting Files:

nihms682901.nxml	application/octet-stream
nihms682901f1.gif	image/gif
nihms682901f1.jpg	image/jpeg
nihms682901f2.gif	image/gif
nihms682901f2.jpg	image/jpeg

No Related Documents.

You May Also Like:

Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy

Personal Author:

Lamb, Molly M.; West, Nancy A.; Ouyang, Lijing; Yang, Michele; Weitzenkamp, David; James, Katherine; Ciafaloni, Emma; Pandya, Shree; DiGuiseppi, Carolyn;

Published:

Mar 30 2016

Source:

J Pediatr. 173:207-213.e3.

Description:

Objectives : To evaluate growth patterns of ambulatory males with Duchenne muscular dystrophy (DMD) treated with corticosteroids compared with ambulatory, steroid-naïlve males with DMD and age-matched unaffected general-population males and to test ...

File Type:

[PDF - 468.85 KB]
Genitourinary health in a population-based cohort of males with Duchenne and Becker muscular dystrophies

Personal Author:

Zhu, Yong; Romitti, Paul A.; Conway, Kristin M. Caspers; Kim, Sunkyung; Zhang, Ying; Yang, Michele; Mathews, Katherine D.;

Corporate Author:

MD STARnet

Published:

Jun 03 2015

Source:

Muscle Nerve. 52(1):22-27.

Description:

Introduction : Genitourinary (GU) health among patients with Duchenne and Becker muscular dystrophies (DBMD) has not been explored using population-based data. : Methods : Medical records of 918 males ascertained by the Muscular Dystrophy Surveillanc...

File Type:

[PDF - 227.87 KB]
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

Personal Author:

Nelson, Christopher E.; Hakim, Chady H.; Ousterout, David G.; Thakore, Pratiksha I.; Moreb, Eirik A.; Rivera, Ruth M. Castellanos; Madhavan, Sarina; Pan, Xiufang; Ran, F. Ann; Yan, Winston X.; Asokan, Aravind; Zhang, Feng; Duan, Dongsheng; Gersbach, Charles A.;

Published:

Dec 31 2015

Source:

Science. 351(6271):403-407.

Description:

Duchenne muscular dystrophy (DMD) is a devastating disease affecting about 1 out of 5000 male births and caused by mutations in the dystrophin gene. Genome editing has the potential to restore expression of a modified dystrophin gene from the native ...

File Type:

[PDF - 1.45 MB]
Neurobehavioral Concerns among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network

Personal Author:

Conway, Kristin Caspers; Mathews, Katherine D.; Paramsothy, Pangaja; Oleszek, Joyce; Trout, Christina; Zhang, Ying; Romitti, Paul A.;

Corporate Author:

MD STAR

Published:

2015 Jul-Aug

Source:

J Dev Behav Pediatr. 36(6):455-463.

Description:

Objective : To describe the occurrence of selected neurobehavioral concerns among males with a dystrophinopathy and explore associations with corticosteroid or supportive device use. : Method : Medical record abstraction of neurobehavioral concerns w...

File Type:

[PDF - 173.02 KB]
Prevalence of Duchenne and Becker Muscular Dystrophies in the United States

Personal Author:

Romitti, Paul A.; Zhu, Yong; Puzhankara, Soman; James, Katherine A.; Nabukera, Sarah K.; Zamba, Gideon K.D.; Ciafaloni, Emma; Cunniff, Christopher; Druschel, Charlotte M.; Mathews, Katherine D.; Matthews, Dennis J.; Meaney, F. John; Andrews, Jennifer G.; Caspers Conway, Kristin M.; Fox, Deborah J.; Street, Natalie; Adams, Melissa M.; Bolen, Julie;

Published:

Feb 16 2015

Source:

Pediatrics. 2015; 135(3):513-521.

Description:

OBJECTIVE : To estimate prevalence of childhood-onset Duchenne and Becker muscular dystrophies (DBMD) in 6 sites in the United States by race/ethnicity and phenotype (Duchenne muscular dystrophy [DMD] or Becker muscular dystrophy [BMD]). : METHODS : ...

File Type:

[PDF - 631.51 KB]